|Awarded On||November 16, 2016|
|Title||Targeting a Growth and Survival Pathway in Bone Tumor Cells.|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Carl A Gregory|
|Cancer Sites||Bone, Breast, Myeloma, Prostate, Sarcoma|
Of the 700,000 newly diagnosed cancers per year in the US, about 40% will eventually affect bone. Bone cancer, or malignant bone disease (MBD), frequently causes catastrophic bone damage in the form of tumor-filled osteolytic bone lesions (OLs). OLs cause fracture, chronic pain, and provide a robust environment for tumor growth, thus reducing the probability of survival. MBD is typically treated by drugs that kill tumors and slow bone loss. Even with these treatments, OLs frequently fail to heal, continually supporting tumor survival while selecting for drug-resistant tumor cells. MBD tumors secrete proteins called Wnt inhibitors (WI) that inhibit the repair of OLs. Of the known WIs, D...